share_log

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

坎託·菲茨傑拉德以增持評級開始對Atossa Therapeutics進行保險,宣佈目標股價爲5美元
Benzinga ·  2023/09/08 08:16

Cantor Fitzgerald analyst Louise Chen initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Overweight rating and announces Price Target of $5.

Cantor Fitzgerald分析師Louise Chen對Atossa治療公司(納斯達克:ATOS)發起增持評級,並宣佈目標價為5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論